Nanexa AB - Home

VISION & MISSION

Nanexa will be a world leading drug development company for Long Acting Injectables, developing a new generation of innovative drug products enabled by our unique PharmaShell® technology”

In its state-of-the-art pilot plant and labs in Uppsala, Nanexa runs the development of own product projects and collaborative projects with other pharmaceutical companies, based on the PharmaShell® system.

Capital markets day at the Royal Swedish Academy of Engineering Sciences IVA in Stockholm

David welcomes

Mårten presents

Kristine presents

Look at all presentations from IVA here

PRESSRELEASES

27 August, 2024

Nanexa publishes interim report for January-June 2024

NEX-22 clinical trial initiated and proceeding with dose escalation as planned

1 August, 2024

Nanexa’s Phase I trial of NEX-22 in type 2- diabetes progresses with next dose group according to plan

Nanexa AB today announces that the company’s Phase 1 study for type 2 diabetes continues dose escalation according to plan with their long-acting depot formulation of the GLP-1 analog liraglutide.